The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein

Cancer Research

Volumn 66, Issue 19, 2006, Pages 9744-9753

  McGahren Murray, Mollianne ^a   Terry, Nicholas H A ^a   Keyomarsi, Khandan ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 4; K 252A; PROTEIN KINASE C INHIBITOR; RETINOBLASTOMA PROTEIN; STAUROSPORINE;

ANIMAL CELL; ARTICLE; BREAST EPITHELIUM; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; FIBROBLAST; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; BREAST; CAMPTOTHECIN; CELL LINE, TRANSFORMED; CYCLIN-DEPENDENT KINASE 4; DOXORUBICIN; DRUG RESISTANCE; ENZYME INDUCTION; EPITHELIAL CELLS; FEMALE; FIBROBLASTS; G1 PHASE; GENES, P53; GENES, RETINOBLASTOMA; HUMANS; MICE; NEOPLASM PROTEINS; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; RETINOBLASTOMA PROTEIN; RNA, SMALL INTERFERING; STAUROSPORINE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33750289449     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1809     Document Type: Article

References (52)

1. Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog Cell Cycle Res 2003;5:527-32.
2. Chen X, Lowe M, Herliczek T, et al. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst 2000;92:1999-2008.
3. Stone S, Dayananth P, Kamb A. Reversible, p16-mediated cell cycle arrest as protection from chemotherapy. Cancer Res 1996;56:3199-202.
4. Ashizawa S, Nishizawa H, Yamada M, et al. Collective inhibition of pRB family proteins by phosphorylation in cells with p16INK4a loss or cyclin E overexpression. J Biol Chem 2001;276:11362-70.
5. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002;1602:73-87. Review.
6. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
7. Shimizu E, Zhao MR, Nakanishi H, et al. Differing effects of staurosporine and UCN-01 on RB protein phosphorylation and expression of lung cancer cell lines. Oncology 1996;53:494-504.
8. Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995;81:323-30.
9. Classon M, Harlow E. The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2002;2:910-7.
10. 1 arrest at two points: effect on retinoblastoma protein phosphorylation and cyclin-dependent kinase 2 in normal and transformed cells. Cancer Res 1994;54:5959-63.
11. 1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. Proc Natl Acad Sci U S A 1996;93:5941-6.
12. 1 arrest in murine embryonic fibroblasts. J Biol Chem 1998;273:3803-7.
13. Zhou W, Lin Y, Wersto R, Chrest J, Gabrielson E. Staurosporine-induced G(1) arrest in cancer cells depends on an intact pRB but is independent of p16 status. Cancer Lett 2002;183:103-7.
14. Gescher A. Staurosporine analogues-pharmacological toys or useful antitumour agents? Crit Rev Oncol Hematol 2000;34:127-35.
15. Pickett CA, Manning N, Akita Y, Gutierrez-Hartmann A. Role of specific protein kinase C isozymes in mediating epidermal growth factor, thyrotropin-releasing hormone, and phorbol ester regulation of the rat prolactin promoter in GH4/GH4C1 pituitary cells. Mol Endocrinol 2002;16:2840-52.
16. Meijer L. Chemical inhibitors of cyclin-dependent kinases. Prog Cell Cycle Res 1995;1:351-63.
17. Konstantinidis AK, Radhakrishnan R, Gu F, Rao RN, Yeh WK. Purification, characterization, and kinetic mechanism of cyclin D1. CDK4, a major target for cell cycle regulation. J Biol Chem 1998;273:26506-15.
18. 0 arrest of human fibroblasts. Exp Cell Res 1995;220:220-5.
19. 1 arrest through down-regulation of cyclin E and cdk2 expression. Cell Struct Funct 1999;24:457-63.
20. 1 arrest during neuronal differentiation of human prostatic cancer TSU-Prl cells by staurosporine. Anticancer Res 2001;21:893-8.
21. 1 arrest is associated with the induction and accumulation of cyclin-dependent kinase inhibitors. Cell Growth Differ 1996;7:1305-13.
22. Zeng YX, el-Deiry WS. Regulation of p21WAF1/CIP1 expression by p53-independent pathways. Oncogene 1996;12:1557-64.
23. Liu Y, Chen JJ, Gao Q, et al. Multiple functions of human papillomavirus type 16 E6 contribute to the immortalization of mammary epithelial cells. J Virol 1999;73:7297-307.
24. Gao Q, Srinivasan S, Boyer SN, Wazer DK, Band V. The E6 oncoproteins of high-risk papillomaviruses bind to a novel putative GAP protein, E6TP1, and target it for degradation. Mol Cell Biol 1999;19:733-44.
25. Dalal S, Gao Q, Androphy EJ, Band V. Mutational analysis of human papillomavirus type 16 E6 demonstrates that p53 degradation is necessary for immortalization of mammary epithelial cells. J Virol 1996;70:683-8.
26. Chen JJ, Reid CE, Band V, Androphy EJ. Interaction of papillomavirus E6 oncoproteins with a putative calcium-binding protein. Science 1995;269:529-31.
27. Band V. Preneoplastic transformation of human mammary epithelial cells. Semin Cancer Biol 1995;6:185-92.
28. Wazer DE, Liu XE, Chu Q, Gao Q, Band V. Immortalization of distinct human mammary epithelial cell types by human papilloma virus 16 E6 or E7. Proc Natl Acad Sci U S A 1995;92:3687-91.
29. Band V, Dalal S, Delmolino L, Androphy EJ. Enhanced degradation of p53 protein in HPV-6 and BPV-1 E6-immortalized human mammary epithelial cells. EMBO J 1993;12:1847-52.
30. Band V, De Caprio JA, Delmolino L, Kulesa V, Sager R. Loss of p53 protein in human papillomavirus type 16 E6-immortalized human mammary epithelial cells. J Virol 1991;65:6671-6.
31. Band V, Zajchowski D, Kulesa V, Sager R. Human papilloma virus DNAs immortalize normal human mammary epithelial cells and reduce their growth factor requirements. Proc Natl Acad Sci U S A 1990;87:463-7.
32. Ratsch SB, Gao Q, Srinivasan S, Wazer DE, Band V. Multiple genetic changes are required for efficient immortalization of different subtypes of normal mammary epithelial cells. Radiat Res 2001;155:143-50.
33. Keyomarsi K, Pardee A. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112-6.
34. Keyomarsi K, Conte D, Jr., Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene 1995;11:941-50.
35. Terry NH, White RA. Cell cycle kinetics estimated by analysis of bromodeoxyuridine incorporation. Methods Cell Biol 2001;63:355-74.
36. 1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene 1998;17:2393-402.
37. Lipinski MM, Jacks T. The retinoblastoma gene family in differentiation and development. Oncogene 1999;18:7873-82.
38. Lin BT, Gruenwald S, Morla AO, Lee W-H, Wang JYL. Retinoblastoma cancer suppressor gene product is a substrate of the cell cycle regulator cdc2 kinase. EMBO J 1991;10:857-64.
39. Lieberman MW, Verbin RS, Landay M, et al. A probable role for protein synthesis in intestinal epithelial cell damage induced in vivo by cytosine arabinoside, nitrogen mustard, or X-irradiation. Cancer Res 1970;30:942-51.
40. Bhuyan BK, Fraser TJ. Antagonism between DNA synthesis inhibitors and protein synthesis inhibitors in mammalian cell cultures. Cancer Res 1974;34:778-82.
41. Pardee AB, James LJ. Selective killing of transformed baby hamster kidney (BHK) cells. Proc Natl Acad Sci USA 1975;72:4994-8.
42. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997;57:4029-35.
43. Akinaga S, Nomura K, Gomi K, Okabe M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother Pharmacol 1993;32:183-9.
44. 2 checkpoint function in cancer cells with disrupted p53. J Natl Cancer Inst 1996;88:956-65.
45. Sugiyama K, Shimizu M, Akiyama T, et al. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G(2) checkpoint abrogation. Int J Cancer 2000;85:703-9.
46. Sampath D, Shi Z, Plunkett W. Inhibition of cyclin-dependent kinase 2 by the Chk1-25A pathway during the S-phase checkpoint activated by fludarabine: dysregulation by 7-hydroxystaurosporine. Mol Pharmacol 2002;62:680-8.
47. Fuse E, Tanii TH, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans. Cancer Res 1999;59:1054-60.
48. Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr Oncol Rep 2002;4:37-46.
49. Hedaya MA, Daoud SS. Tissue distribution and plasma pharmacokinetics of UCN-01 at steady-state and following bolus administration in rats: influence of human α1-acid glycoprotein binding. Anticancer Res 2001;21:4005-10.
50. Fuse E, Hashimoto A, Sato N, et al. Physiological modeling of altered pharmacokinetics of a novel anticancer drug, UCN-01 (7-hydroxystaurosporine), caused by slow dissociation of UCN-01 from human α1-acid glycoprotein. Pharm Res 2000;17:553-64.
51. Fuse E, Tanii H, Kurata N, et al. Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human α1-acid glycoprotein. Cancer Res 1998;58:3248-53.
52. Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to α1-acid glycoprotein in humans. Cancer Res 1999;59:1054-60.